Literature DB >> 2994554

Neurotransmitter receptor alterations in Huntington's disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes.

P J Whitehouse, R R Trifiletti, B E Jones, S Folstein, D L Price, S H Snyder, M J Kuhar.   

Abstract

In vitro receptor autoradiography was used to construct semiquantitative maps of subtypes of muscarinic cholinergic (labeled with [3H]N-methylscopolamine), benzodiazepine ([3H]flunitrazepam), gamma-aminobutyric acid ([3H]muscimol), dopamine, and serotonin ([3H]spiperone) receptors in frontal cortex, parietal cortex, caudate, putamen, and globus pallidus in tissue sections from 5 patients with clinically well-evaluated Huntington's disease and 5 controls matched with respect to age, sex, and postmortem delay. Homogenates were prepared from the remaining cortical and striatal tissue and used to characterize pharmacologically these same receptors, as well as histamine, adenosine, and nitrendipine receptors. Neuronal loss and gliosis were assessed in the contralateral formalin-fixed caudate and putamen. All binding sites measured (except serotonin) were reduced relative to control values in striatum primarily because of changes in the number of receptors rather than in affinity. Autoradiographic studies generally revealed that these changes were greater in the caudate than the putamen, paralleling the more severe neuropathological changes present in the caudate. In addition, autoradiographic studies demonstrated an increase in gamma-aminobutyric acid-related receptors in the globus pallidus. In the cortex, receptor alterations were limited to an increase in the number of benzodiazepine receptors in the frontal cortex which was most prominent in superficial cortical layers.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2994554     DOI: 10.1002/ana.410180207

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  8 in total

1.  Glutamate uptake is reduced in prefrontal cortex in Huntington's disease.

Authors:  Bjørnar Hassel; Shoshi Tessler; Richard L M Faull; Piers C Emson
Journal:  Neurochem Res       Date:  2007-08-29       Impact factor: 3.996

2.  Genetic markers in Huntington's disease.

Authors:  E M Frohman; J B Martin
Journal:  West J Med       Date:  1987-10

3.  Loss of muscarinic cholinergic receptors from the temporal cortex of alcohol abusers.

Authors:  G Freund; W E Ballinger
Journal:  Metab Brain Dis       Date:  1989-06       Impact factor: 3.584

4.  Detection of benzodiazepine receptor occupancy in the human brain by positron emission tomography.

Authors:  H Shinotoh; M Iyo; T Yamada; O Inoue; K Suzuki; T Itoh; H Fukuda; T Yamasaki; Y Tateno; K Hirayama
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.

Authors:  Izaskun Villar-Menéndez; Marta Blanch; Shiraz Tyebji; Thais Pereira-Veiga; José Luis Albasanz; Mairena Martín; Isidre Ferrer; Esther Pérez-Navarro; Marta Barrachina
Journal:  Neuromolecular Med       Date:  2013-02-06       Impact factor: 3.843

6.  11C-labeled 2'-iododiazepam for PET studies of benzodiazepine receptors: synthesis and comparison of biodistribution with its radioiodinated compound.

Authors:  Y Iida; H Saji; Y Magata; J Konishi; I Nakatsuka; A Yoshitake; A Yokoyama
Journal:  Ann Nucl Med       Date:  1994-02       Impact factor: 2.668

Review 7.  Current status of PET imaging in Huntington's disease.

Authors:  Gennaro Pagano; Flavia Niccolini; Marios Politis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-22       Impact factor: 9.236

Review 8.  Purinergic Signaling in the Pathophysiology and Treatment of Huntington's Disease.

Authors:  Melissa Talita Wiprich; Carla Denise Bonan
Journal:  Front Neurosci       Date:  2021-07-01       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.